Aegerion's公司研制开发的洛美他派(lomitapide)甲磺酸盐于2012年12月21日由美国FDA批准在美国上市,商品名为Juxtapid。该药为胶囊剂,用于治疗纯合子家族性高胆固醇血症(HoFH)。该药获准与低脂饮食和其他降脂药物一起使用治疗HoFH,可降低患者的低密度脂蛋白胆固醇、总胆固醇、载脂蛋白B和非高密度脂蛋白 Lomitapide mesylate, developed by Aegerion's, was marketed in the United States by the U.S. FDA on December 21, 2012 under the tradename Juxtapid. This medicine is a capsule for the treatment of homozygous familial hypercholesterolemia (HoFH). The drug is approved for use with low fat diets and other lipid-lowering drugs in the treatment of HoFH, lowering LDL cholesterol, total cholesterol, apolipoprotein B, and non-HDL cholesterol